Response rates in categorical rating scales for relief from symptoms at weeks 4, 8 and 12—frequency table per visit
| Symptom† | Week 4 | Week 8 | Week 12 | |||
| Cannabis extract (N=143) | Placebo (N=134) | Cannabis extract (N=143) | Placebo (N=134) | Cannabis extract (N=143) | Placebo (N=134) | |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Muscle stiffness | 44 (30.8) | 20 (14.9**) | 41 (28.7) | 22 (16.4***) | 42 (29.4) | 21 (15.7***) |
| Body pain | 40 (28.0) | 23 (17.2**) | 43 (30.1) | 26 (19.4***) | 40 (28.0) | 25 (18.7) |
| Muscle spasms | 40 (28.0) | 26 (19.4*) | 42 (29.4) | 29 (21.6*) | 44 (30.8) | 18 (13.4***) |
| Sleep quality | 60 (42.0) | 25 (18.7***) | 51 (35.7) | 23 (17.2***) | 48 (33.6) | 26 (19.4**) |
Difference between cannabis extract and placebo: *p<0.025, **p<0.005 or ***p<0.0025, respectively (one sided logistic regression with ambulatory status, spasticity medication and region as fixed factors).
↵† Assessed by an 11 point numerical Likert scale (0=very much better, …, 10=very much worse than symptoms prior to start of study); categories 0–3 are defined as relief—that is, as clinically relevant response.
%, percentage based on N; n, number of patients in specified category; N, number of patients in specified treatment group.